

DAFTAR PUSTAKA

- Agaba, D. C., Migisha, R., Namayanja, R., Katamba, G., Lugobe, H. M., Aheisibwe, H., Twesigomwe, G., & Ashaba, S. (2019). Prevalence and Associated Factors of Metabolic Syndrome among Patients with Severe Mental Illness Attending a Tertiary Hospital in Southwest Uganda. *BioMed Research International*, 2019, 1096201. <https://doi.org/10.1155/2019/1096201>
- Ahmed, M., Griffin, D., O'Toole, R., & McDonald, C. (2009). Clozapine-Induced Severe Mixed Hyperlipidemia: A case report. *General Hospital Psychiatry*, 31(1), 93–96. <https://doi.org/10.1016/j.genhosppsych.2008.07.003>
- Akbartabar Toori, M., Kiani, F., Sayehmiri, F., Sayehmiri, K., Mohsenzadeh, Y., Ostovar, R., Angha, P., & Mohsenzadeh, Y. (2018). Prevalence of Hypercholesterolemia, High LDL, and Low HDL in Iran: A Systematic Review and Meta-Analysis. *Iranian Journal of Medical Sciences*, 43(5), 449–465.
- Akhfiya, M., & Syamsianah, A. (2018). *Kadar Kolesterol Total Wanita Menopause Hiperkolesterolemia Sesudah Pemberian Teh Buah Tin*. 5.
- Al-Zahrani, J., Shubair, M. M., Al-Ghamdi, S., Alrasheed, A. A., Alduraywish, A. A., Alreshidi, F. S., Alshahrani, S. M., Alsalamah, M., Al-Khateeb, B. F., Ashathri, A. I., El-Metwally, A., & Aldossari, K. K. (2021). The Prevalence Of Hypercholesterolemia And Associated Risk Factors In Al-Kharj Population, Saudi Arabia: A Cross-Sectional Survey. *BMC Cardiovascular Disorders*, 21(1), 22. <https://doi.org/10.1186/s12872-020-01825-2>
- Andari, S. (2017). *Pelayanan Sosial Panti Berbasis Agama dalam Merehabilitasi Penderita Skizofrenia*. 16(2), 195–208.
- Aryani, F., & Sari, O. (2016). *Gambaran Pola Penggunaan Antipsikotik Pada Pasen Skizofrenia Di Ruang Rawat Inap Rumah Sakit Jiwa*. 6, 6.
- Ball, M. P., Hooper, E. T., Skipwith, D. F., & Cates, M. E. (2005). Clozapine-Induced Hyperlipidemia Resolved After Switch to Aripiprazole Therapy. *Annals of Pharmacotherapy*, 39(9), 1570–1572. <https://doi.org/10.1345/aph.1E682>
- Brunero, S., Lamont, S., & Fairbrother, G. (2009). Prevalence and Predictors of Metabolic Syndrome Among Patients Attending an Outpatient Clozapine Clinic in Australia. *Archives of Psychiatric Nursing*, 23(3), 261–268. <https://doi.org/10.1016/j.apnu.2008.06.007>
- Cai, H. L., Tan, Q. Y., Jiang, P., Dang, R. L., Xue, Y., Tang, M. M., Xu, P., Deng, Y., Li, H. D., & Yao, J. K. (2015). A Potential Mechanism Underlying Atypical Antipsychotics-Induced Lipid Disturbances. *Translational Psychiatry*, 5(10), e661–e661. <https://doi.org/10.1038/tp.2015.161>
- Carpenter, W. T., & Buchanan, R. W. (1994). Schizophrenia. *New England Journal of Medicine*, 330(10), 681–690. <https://doi.org/10.1056/NEJM199403103301006>
- Casey, D. E. (2004). *Dyslipidemia and Atypical Antipsychotic Drugs*. 9.

- Chang, H.-Y., Yeh, W.-T., Chang, Y.-H., Tsai, K.-S., & Pan, W.-H. (2002). *Prevalence of Dyslipidemia and Mean Blood Lipid Values in Taiwan: Results from the Nutrition and Health Survey in Taiwan*. 11.
- Chiang, H. L., Liu, C. C., & Hwang, T. J. (2009). Rapid Dose-Dependent Effect Of Clozapine On A Schizophrenic Patient's Lipid Profile. *Journal of Psychopharmacology (Oxford, England)*, 23(4), 465–467. <https://doi.org/10.1177/0269881108091255>
- Chisholm-Burns, M. A. (Ed.). (2016). *Pharmacotherapy principles & practice* (Fourth edition). McGraw-Hill Education.
- Cho, S. M. J., Lee, H. J., Shim, J. S., Song, B. M., & Kim, H. C. (2020). Associations Between Age And Dyslipidemia Are Differed By Education Level: The Cardiovascular and Metabolic Diseases Etiology Research Center (CMERC) cohort. *Lipids in Health and Disease*, 19(1), 12. <https://doi.org/10.1186/s12944-020-1189-y>
- Correll, C. U., Frederickson, A. M., Kane, J. M., & Manu, P. (2007). Does Antipsychotic Polypharmacy Increase The Risk For Metabolic Syndrome? *Schizophrenia Research*, 89(1–3), 91–100. <https://doi.org/10.1016/j.schres.2006.08.017>
- Cui, M., Chiang, C., Cui, R., Honjo, K., Yatsuya, H., Watson, B. M., Ikerdeu, E., Mita, T., Madraisau, S., Aoyama, A., & Iso, H. (2019). Prevalence and Correlates of Dyslipidemia Among Men and Women in Palau: Findings of the Palau STEPS Survey 2011–2013. *Journal of Epidemiology*, 29(3), 97–103. <https://doi.org/10.2188/jea.JE20170127>
- Dania, H., Faridah, I. N., Rahmah, K. F., Abdulah, R., Barliana, M. I., & Perwitasari, D. A. (2019). Hubungan Pemberian Terapi Antipsikotik terhadap Kejadian Efek Samping Sindrom Ekstrapiramidal pada Pasien Rawat Jalan di Salah Satu Rumah Sakit di Bantul, Yogyakarta. *Indonesian Journal of Clinical Pharmacy*, 8(1). <https://doi.org/10.15416/ijcp.2019.8.1.19>
- Destiana, D., & Timan, I. S. (2018). The Relationship Between Hypercholesterolemia As A Risk Factor For Stroke And Blood Viscosity Measured Using Digital Microcapillary®. *Journal of Physics: Conference Series*, 1073, 042045. <https://doi.org/10.1088/1742-6596/1073/4/042045>
- DiPiro, J. T. (Ed.). (2020). *Pharmacotherapy: A pathophysiologic approach* (Eleventh edition). McGraw Hill Medical.
- Fatmah, R. A. (2010). *Gizi Usia Lanjut*. Erlangga.
- Gogos, A., Sbisà, A. M., Sun, J., Gibbons, A., Udawela, M., & Dean, B. (2015). A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings. *International Journal of Endocrinology*, 2015, 615356. <https://doi.org/10.1155/2015/615356>
- Gupta, R., Sharma, M., Goyal, N. K., Bansal, P., Lodha, S., & Sharma, K. K. (2016). Gender Differences In 7 Years Trends In Cholesterol Lipoproteins And Lipids In India: Insights From A Hospital Database. *Indian Journal of Endocrinology and Metabolism*, 20(2), 211–218. <https://doi.org/10.4103/2230-8210.176362>

- Hariadini, A. L., Sidharta, B., Ebtavanny, T. gusti, & Minanga, E. putri. (2020). Hubungan Tingkat Pengetahuan Dan Ketepatan Penggunaan Obat Simvastatin Pada Pasien Hiperkolesterolemia Di Apotek Kota Malang. *Pharmaceutical Journal of Indonesia*, 005(02), 91–96. <https://doi.org/10.21776/ub.pji.2020.005.02.4>
- Ikawati, Z., & Kristanto, C. S. (2021). *Perbandingan Efektivitas Regimen Terapi Antipsikotik Pasien Schizophrenia di RSJ Dr. Ernaldi Bahar Palembang*. 17(2), 11.
- Jiang, W.-L., Cai, D.-B., Yin, F., Zhang, L., Zhao, X.-W., He, J., Ng, C. H., Ungvari, G. S., Sim, K., Hu, M.-L., Zheng, W., & Xiang, Y.-T. (2020). Adjunctive Metformin For Antipsychotic-Induced Dyslipidemia: A Meta-Analysis Of Randomized, Double-Blind, Placebo-Controlled Trials. *Translational Psychiatry*, 10(1), 117. <https://doi.org/10.1038/s41398-020-0785-y>
- Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., van Os, J., & Insel, T. R. (2015). Schizophrenia. *Nature Reviews. Disease Primers*, 1, 15067. <https://doi.org/10.1038/nrdp.2015.67>
- Krakowski, M., Czobor, P., & Citrome, L. (2009). Weight Gain, Metabolic Parameters, And The Impact Of Race In Aggressive Inpatients Randomized To Double-Blind Clozapine, Olanzapine Or Haloperidol. *Schizophrenia Research*, 110(1–3), 95–102. <https://doi.org/10.1016/j.schres.2009.02.006>
- Kumar, M., & Sidana, A. (2017). Clozapine-induced Acute Hypertriglyceridemia. *Indian Journal of Psychological Medicine*, 39(5), 682–684. <https://doi.org/10.4103/0253-7176.217031>
- Lally, J., & MacCabe, J. H. (2015). Antipsychotic Medication In Schizophrenia: A review. *British Medical Bulletin*, 114(1), 169–179. <https://doi.org/10.1093/bmb/ldv017>
- Lamberti, J. S., Olson, D., Crilly, J. F., Olivares, T., Williams, G. C., Tu, X., Tang, W., Wiener, K., Dvorin, S., & Dietz, M. B. (2006). Prevalence of the Metabolic Syndrome Among Patients Receiving Clozapine. *American Journal of Psychiatry*, 163(7), 1273–1276. <https://doi.org/10.1176/ajp.2006.163.7.1273>
- Laporan nasional Riskesdas 2018*. (2019). Lembaga Penerbit Balitbangkes, Kementerian Kesehatan, Republik Indonesia, Badan Penelitian dan Pengembangan Kesehatan.
- Leadbetter, R., Shutty, M., Pavalonis, D., Vieweg, V., Higgins, P., & Downs, M. (1992). Clozapine-Induced Weight Gain: Prevalence And Clinical Relevance. *The American Journal of Psychiatry*, 149(1), 68–72. <https://doi.org/10.1176/ajp.149.1.68>
- Lexi-Comp, I. (2017). *Drug information handbook: A clinically relevant resource for all healthcare professionals*.
- Li, R., Ma, X., Wang, G., Yang, J., & Wang, C. (2016). Why Sex Differences In Schizophrenia? *Journal of Translational Neuroscience*, 1(1), 37–42.
- Lindenmayer, J.-P., Czobor, P., Volavka, J., Citrome, L., Sheitman, B., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2003). Changes in

- Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics. *American Journal of Psychiatry*, 160(2), 290–296. <https://doi.org/10.1176/appi.ajp.160.2.290>
- McNeil, S. E., Gibbons, J. R., & Cogburn, M. (2022). Risperidone. In *StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK459313/>
- Mueser, K. T., & Jeste, D. V. (Eds.). (2008). *Clinical handbook of schizophrenia*. Guilford Press.
- Mueser, K. T., & McGurk, S. R. (2004). Schizophrenia. *Lancet (London, England)*, 363(9426), 2063–2072. [https://doi.org/10.1016/S0140-6736\(04\)16458-1](https://doi.org/10.1016/S0140-6736(04)16458-1)
- Mukaddas, A., Faustin, I., & Fahrul, F. (2014). Rasionalitas Penggunaan Antipsikotik pada Pasien Skizofrenia di Instalasi Rawat Inap Jiwa RSD Madani Provinsi Sulawesi Tengah Periode Januari-April 2014. *Online Journal of Natural Science*, 3(2), 18–29.
- Mulyani, N. S., Al Rahmad, A. H., & Jannah, R. (2018). Faktor Resiko Kadar Kolesterol Darah Pada Pasien Rawat Jalan Penderita Jantung Koroner di RSUD Meuraxa. *Action: Aceh Nutrition Journal*, 3(2), 132. <https://doi.org/10.30867/action.v3i2.113>
- Ortiz-Orendain, J., Castiello-de Obeso, S., Colunga-Lozano, L. E., Hu, Y., Maayan, N., & Adams, C. E. (2017). Antipsychotic Combinations For Schizophrenia. *The Cochrane Database of Systematic Reviews*, 6, CD009005. <https://doi.org/10.1002/14651858.CD009005.pub2>
- Özdemir, V., Masellis, M., Basile, V. S., Kalow, W., Meltzer, H. Y., Lieberman, J. A., & Kennedy, J. L. (1999). Variability in Response to Clozapine: Potential Role of Cytochrome P450 1A2 and the Dopamine D₄ Receptor Gene. *CNS Spectrums*, 4(6), 30–34, 47–56. <https://doi.org/10.1017/S109285290001186X>
- Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., & Howes, O. D. (2020). Comparative Effects Of 18 Antipsychotics On Metabolic Function In Patients With Schizophrenia, Predictors Of Metabolic Dysregulation, And Association With Psychopathology: A Systematic Review And Network Meta-Analysis. *The Lancet. Psychiatry*, 7(1), 64–77. [https://doi.org/10.1016/S2215-0366\(19\)30416-X](https://doi.org/10.1016/S2215-0366(19)30416-X)
- Rahman, S., & Marwaha, R. (2022). Haloperidol. In *StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK560892/>
- Sadock, B., & Sadock, V. (2002). Kaplan and Sadock's Comprehensive Textbook of Psychiatry, 7th ed., vols. 1, 2. *American Journal of Psychiatry*, 159(2), 327–327. <https://doi.org/10.1176/appi.ajp.159.2.327>
- Solberg, D. K., Bentsen, H., Refsum, H., & Andreassen, O. A. (2016). Lipid Profiles In Schizophrenia Associated With Clinical Traits: A Five Year Follow-Up Study. *BMC Psychiatry*, 16(1), 299. <https://doi.org/10.1186/s12888-016-1006-3>
- Srirenakumar, V., Huang, E., & Müller, D. J. (2015). Pharmacogenetics Of Clozapine Treatment Response And Side-Effects In Schizophrenia: An update. *Expert Opinion on Drug Metabolism & Toxicology*, 11(11), 1709–1731. <https://doi.org/10.1517/17425255.2015.1075003>

- Stepnicki, P., Kondej, M., & Kaczor, A. A. (2018). Current Concepts and Treatments of Schizophrenia. *Molecules (Basel, Switzerland)*, 23(8), E2087. <https://doi.org/10.3390/molecules23082087>
- Stilo, S. A., & Murray, R. M. (2019). Non-Genetic Factors in Schizophrenia. *Current Psychiatry Reports*, 21(10), 100. <https://doi.org/10.1007/s11920-019-1091-3>
- Storch Jakobsen, A., Speyer, H., Nørgaard, H. C. B., Hjorthøj, C., Krogh, J., Mors, O., & Nordentoft, M. (2018). Associations Between Clinical And Psychosocial Factors And Metabolic And Cardiovascular Risk Factors In Overweight Patients With Schizophrenia Spectrum Disorders – Baseline And Two-Years Findings From The CHANGE trial. *Schizophrenia Research*, 199, 96–102. <https://doi.org/10.1016/j.schres.2018.02.047>
- Taub, S., Hoshen, M., Balicer, R., Kamhi-Nesher, S., Weizman, A., & Krivoy, A. (2020). Metabolic Predictors For Mortality Among Patients Treated With Long-Term Clozapine – A Longitudinal Study. *European Neuropsychopharmacology*, 41, 63–69. <https://doi.org/10.1016/j.euroneuro.2020.09.002>
- Ujiani, S. (2015). Hubungan Antara Usia dan Jenis Kelamin dengan Kadar Kolesterol Penderita Obesitas RSUD Abdul Moeloek Provinsi Lampung. 48 *Jurnal Kesehatan*, 4(1), 43–48.
- Vallianatou, K. (2016). Antipsychotics. *Medicine*, 44(12), 748–752. <https://doi.org/10.1016/j.mpmed.2016.09.018>
- Ventriglio, A., Baldessarini, R. J., Vitrani, G., Bonfitto, I., Cecere, A. C., Rinaldi, A., Petito, A., & Bellomo, A. (2018). Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics. *Frontiers in Psychiatry*, 9, 744. <https://doi.org/10.3389/fpsy.2018.00744>
- Wells, B. G., DiPiro, J. T., Schwinghammer, T. L., & DiPiro, C. V. (2015). *Pharmacotherapy handbook*.
- Wooltorton, E. (2002). Antipsychotic clozapine (Clozaril): Myocarditis and cardiovascular toxicity. *CMAJ: Canadian Medical Association Journal = Journal de l'Association Medicale Canadienne*, 166(9), 1185–1186.
- Wu, R.-R., Zhao, J.-P., Liu, Z.-N., Zhai, J.-G., Guo, X.-F., Guo, W.-B., & Tang, J.-S. (2006). Effects Of Typical And Atypical Antipsychotics On Glucose-Insulin Homeostasis And Lipid Metabolism In First-Episode Schizophrenia. *Psychopharmacology*, 186(4), 572–578. <https://doi.org/10.1007/s00213-006-0384-5>
- Yulianty, M. D., Cahaya, N., & Srikartika, V. M. (2017). Studi Penggunaan Antipsikotik dan Efek Samping pada Pasien Skizofrenia di Rumah Sakit Jiwa Sambang Lihum Kalimantan Selatan. *Jurnal Sains Farmasi & Klinis*, 3(2), 153. <https://doi.org/10.29208/jsfk.2017.3.2.108>